HE4 as a biomarker for ovarian and endometrial cancer management

Expert Review of Molecular Diagnostics

Volumn 9, Issue 6, 2009, Pages 555-566

  Li, Jinping ^a   Dowdy, Sean ^b   Tipton, Tracy ^a   Podratz, Karl ^b   Lu, Wei Guo ^c   Xie, Xing ^c   Jiang, Shi Wen ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer antigen 125; Cancer diagnosis and treatment; Endometrial cancer; Human epididymis protein 4; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CATHEPSIN B; CHITINASE 3 LIKE 1; CYTOKERATIN 20; GLYCAN DERIVATIVE; HUMAN EPIDIDYMIS PROTEIN 4; INTERLEUKIN 6; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; OSTEOPONTIN; PROLACTIN; PROTEIN BCL 2; PROTEIN DERIVATIVE; SOMATOMEDIN B; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; ENDOMETRIUM CANCER; EPIDIDYMIS; GENE STRUCTURE; HUMAN; HUMAN EPIDIDYMIS PROTEIN 4 GENE; MORPHOLOGY; PAPANICOLAOU TEST; PATHOGENESIS; REVIEW; TUMOR GENE; UNITED STATES; UTERINE CERVIX CANCER;

EARLY DETECTION OF CANCER; ENDOMETRIAL NEOPLASMS; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 69949188760     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.39     Document Type: Review

References (82)

1. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 112, 40-46 (2009). • Communicates the crucial need for accurate endometrial cancer (EC)/ovarian cancer (OC) biomarkers. The authors note the poor prognosis associated with advanced-stage detection of either disease, along with the favorable prognosis typical of patients for which early detection is realized.
2. Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J. Clin. Oncol. 25, 4159-4161 (2007). • Points to the fact that no reliable markers for detection of either OC or EC are currently available.
3. Earle CC, Schrag D, Neville BA et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl Cancer Inst. 98, 172-180 (2006). (Pubitemid 43205479)
4. McGowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet. Gynecol. 65, 568-572 (1985).
5. Olaitan A, Weeks J, Mocroft A et al. The surgical management of women with ovarian cancer in the south west of England. Br. J. Cancer 85, 1824-1830 (2001).
6. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 16 (Suppl. 1), 11-17 (2006).
7. Engelen MJ, Kos HE, Willemse PH et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106, 589-598 (2006).
8. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol. Oncol. 99, 447-461 (2005) (Pubitemid 41502860)
9. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol. Oncol. 84, 36-42 (2002). (Pubitemid 34056463)
10. Leitzmann MF, Koebnick C, Danforth KN et al. Body mass index and risk of ovarian cancer. Cancer 115, 812-822 (2009).
11. Parkin DM. Cancers of the breast, endometrium and ovary: geographic correlations. Eur. J. Cancer Clin. Oncol. 25, 1917-1925 (1989).
12. Ben-Arie A, Huszar M, Ben-Zvi N et al. The role of L1-CAM immunohistochemial staining in the diagnosis of abdominal-pelvic cancer of uncertain primary site in women. Eur. J. Surg. Oncol. 34, 795-799 (2008). (Pubitemid 351818233)
13. Session DR, Lee GS, Choi J, Wolgemuth DJ. Expression of cyclin E in gynecologic malignancies. Gynecol. Oncol. 72, 32-37 (1999).
14. Duggan BD, Dubeau L. Genetics and biology of gynecologic cancer. Curr. Opin. Oncol. 10, 439-446 (1998).
15. Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11, 6422-6430 (2005). (Pubitemid 41338978)
16. Jonson AL, Bliss RL, Truskinovsky A et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol. Oncol. 100, 561-564 (2006). (Pubitemid 43246873)
17. Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108, 402-408 (2008). •• Illustrates human epididymis protein (HE)4's superiority over cancer antigen (CA)-125 in OC detection. The authors examined 233 patients including 67 OC and 166 benign ovarian neoplasms. As a single marker, HE4 had the highest sensitivity at 72.9% (specificity 95%). The combination of HE4 plus CA125 gave rise to the highest sensitivity at 76.4% (specificity 95%).
18. Rustin GJ, Bast RC Jr, Kelloff GJ et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 10, 3919-3926 (2004).
19. Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887 (1983).
20. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 8, 813-821 (2007). •• Describes the frequency of false-positivity in CA-125 assay for OC detection. The authors point out that CA-125 is expressed in many normal Müllerian cell types, and its serum elevation is often attributable to nonmalignant conditions, such as menstruation, the first trimester of pregnancy and the postpartum state.
21. Bast RC Jr, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337 (1981). (Pubitemid 12235035)
22. Kabawat SE, Bast RC Jr, Bhan AK et al. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol. 2, 275-285 (1983).
23. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am. J. Clin. Pathol. 79, 98-104 (1983).
24. van der Burg ME, Lammes FB, van Putten WL, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol. Oncol. 30, 307-312 (1988). (Pubitemid 18179514)
25. Nagele F, Petru E, Medl M et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. 86, 259-264 (1995).
26. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev. 21, 215-245 (1995).
27. Fayers PM, Rustin G, Wood R et al. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int. J. Gynecol. Cancer 3, 285-292 (1993). (Pubitemid 23290116)
28. van Dalen A, Favier J, Burges A et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol. Oncol. 79, 444-450 (2000).
29. Hogdall CK, Norgaard-Pedersen B, Mogensen O. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res. 22, 1765-1768 (2002). (Pubitemid 34839193)
30. Hawkins RE, Roberts K, Wiltshaw E et al. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br. J. Obstet. Gynaecol. 96, 1395-1399 (1989). (Pubitemid 20020045)
31. Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet. Gynecol. Scand. 69, 423-429 (1990).
32. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
33. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92, 699-708 (2000).
34. Rustin GJ, Timmers P, Nelstrop A et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J. Clin. Oncol. 24, 45-51 (2006). (Pubitemid 46630492)
35. Grover S, Koh H, Weideman P, Quinn MA The effect of the menstrual cycle on serum CA 125 levels: a population study. Am. J. Obstet. Gynecol. 167, 1379-1381 (1992).
36. Bergmann JF, Beaugrand M, Labadie H, Bidart JM, Bohuon C. CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases. Clin. Chim. Acta 155, 163-165 (1986). (Pubitemid 16045574)
37. Havrilesky LJ, Whitehead CM, Rubatt JM et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 110, 374-382 (2008).
38. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed. Pharmacother. 58, 24-38 (2004). (Pubitemid 38117046)
39. Yurkovetsky Z, Ta'asan S, Skates S et al. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol. Oncol. 107, 58-65 (2007). •• Illustrates prolactin's accuracy as a marker for early EC detection. The authors examined a panel of 64 serum biomarkers in a study involving 115 EC patients and 135 health controls and determined that prolactin, with a sensitivity of 98.3% at 98% specificity, was the most accurate marker for the diagnosis of EC.
40. Niloff JM, Klug TL, Schaetzl E et al. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am. J. Obstet. Gynecol. 148, 1057-1058 (1984). • Highlights the limitations of CA-125 for EC detection. Since it is elevated in only 10-20% of women with stage I EC and 25% of those with asymptomatic recurrences, CA-125's use in EC detection is largely limited to later stage detection.
41. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: a useful marker in endometrial carcinoma. Am. J. Obstet. Gynecol. 155, 1097-1102 (1986).
42. Brand JM, Frohn C, Cziupka K et al. Prolactin triggers pro-inflammatory immune responses in peripheral immune cells. Eur. Cytokine Netw. 15, 99-104 (2004). (Pubitemid 38980082)
43. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog. Horm. Res. 57, 435-455 (2002).
44. Clapp C, Lopez-Gomez FJ, Nava G et al. Expression of prolactin mRNA and of prolactin-like proteins in endothelial cells: evidence for autocrine effects. J. Endocrinol. 158, 137-144 (1998). (Pubitemid 28322519)
45. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J. Endocrinol. 173, 219-238 (2002). (Pubitemid 34552451)
46. Leiser AL, Hamid AM, Blanchard R. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. Gynecol. Oncol. 94, 567-571 (2004). (Pubitemid 39024569)
47. Kirchhoff C, Osterhoff C, Habben I, Ivell R. Cloning and analysis of mRNAs expressed specifically in the human epididymis. Int. J. Androl. 13, 155-167 (1990). •• Initial identification of HE4 by differential cDNA screening in human epididymis tissue. (Pubitemid 20116937)
48. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod. 45, 350-357 (1991).
49. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21, 2768-2773 (2002). (Pubitemid 34478335)
50. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 19, 847-853 (2006).
51. Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem. Biophys. Res. Commun. 333, 383-389 (2005). (Pubitemid 40848302)
52. Ranganathan S, Simpson KJ, Shaw DC, Nicholas KR The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling. J. Mol. Graph. Model 17, 106-113, 134-1106 (1999).
53. Schalkwijk J, Wiedow O, Hirose S. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem. J. 340 (Pt 3), 569-577 (1999). (Pubitemid 29312852)
54. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem. J. 368, 233-242 (2002). (Pubitemid 35463426)
55. Iwabuchi H, Sakamoto M, Sakunaga H et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res. 55, 6172-6180 (1995). • Highlights the frequency of 20q13 gains in various malignancies, including gastric, oral, breast, ovarian, colon, pancreatic, stomach and uterine. The 20q13 locus harbors the HE4 gene among other whey acidic protein-encoding genes.
56. Sonoda G, Palazzo J, du Manoir S et al. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 20, 320-328 (1997). (Pubitemid 27520080)
57. Kiechle M, Jacobsen A, Schwarz-Boeger U et al. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 91, 534-540 (2001).
58. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P. Secretory leukocyte protease inhibitor in cancer development. Ann. NY Acad. Sci. 1028, 380-389 (2004). (Pubitemid 40361839)
59. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidicprotein motifs and cancer. Lancet Oncol. 7, 167-174 (2006).
60. Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. 265, 14791-14795 (1990). (Pubitemid 20296164)
61. Hellstrom I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63, 3695-3700 (2003). •• Describes a successful method for obtaining mouse monoclonal antibodies to HE4 epitopes for construction of a double-determinant 'sandwich' ELISA.
62. Schummer M, Ng WV, Bumgarner RE et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238, 375-385 (1999). (Pubitemid 29446174)
63. Ono K, Tanaka T, Tsunoda T et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 60, 5007-5011 (2000). (Pubitemid 30739750)
64. Hough CD, Sherman-Baust CA, Pizer ES et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60, 6281-6287 (2000).
65. Shridhar V, Lee J, Pandita A et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 61, 5895-5904 (2001). (Pubitemid 32769109)
66. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 98, 1176-1181 (2001).
67. Schaner ME, Ross DT, Ciaravino G et al. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 14, 4376-4386 (2003). (Pubitemid 37444641)
68. Drapkin R, von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65, 2162-2169 (2005). (Pubitemid 40490123)
69. Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv. Exp. Med. Biol. 622, 15-21 (2008).
70. Lowe KA, Shah C, Wallace E et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 17, 2480-2487 (2008).
71. Scholler N, Lowe KA, Bergan LA et al. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin. Cancer Res. 14, 2647-2655 (2008). •• Describes a method for obtaining in vivo biotinylated HE4 antibodies, or 'biobodies', from diploid yeast transformed with recombinant plasmid DNA. The authors determined that the biobodies were cheaper, easier to use and more accurate than HE4 antibodies obtained via other methods.
72. Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100, 1315-1319 (2009). •• Describes HE4's ability to discriminate EC and OC from endometriotic lesions. This study further substantiates HE4's superiority over CA125 in discerning between malignancies and benign gynecologic diseases.
73. Dong L, Chang XH, Ye X et al. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Zhonghua Fu Chan Ke Za Zhi 43, 931-936 (2008).
74. Bristow RE, Santillan A, Diaz-Montes TP et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 109, 1513-1522 (2007). (Pubitemid 46595686)
75. Moore RG, Brown AK, Miller MC et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 110, 196-201 (2008). •• Illustrates HE4's superiority over CA-125 in OC detection. The authors examined 327 patients including 171 EC and 156 healthy controls. As a single marker, HE4 had the highest sensitivity regardless of which stage(s) was included. The combination of HE4 plus CA125 gave rise to the highest sensitivity when only stages II-IV were included, but the addition of CA125 to the HE4 assay for detection of stage I EC did not significantly increase the sensitivity.
76. Sood AK, Buller RE, Burger RA et al. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet. Gynecol. 90, 441-447 (1997).
77. Vuento MH, Stenman UH, Pirhonen JP et al. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecol. Oncol. 64, 141-146 (1997).
78. Ginath S, Menczer J, Fintsi Y et al. Tissue and serum CA125 expression in endometrial cancer. Int. J. Gynecol. Cancer 12, 372-375 (2002). (Pubitemid 34839835)
79. Hsieh CH, ChangChien CC, Lin H et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol. Oncol. 86, 28-33 (2002). (Pubitemid 34757047)
80. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA-125 levels in treating endometrial cancer. J. Reprod. Med. 50, 585-590 (2005).
81. American Cancer Society www.cancer.org
82. Fujirebio Diagnostic, Inc., PA, USA www.fdi.com